

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10663471/publications.pdf>

Version: 2024-02-01

87
papers

6,580
citations

117453

34
h-index

62479

80
g-index

89
all docs

89
docs citations

89
times ranked

7138
citing authors

#	ARTICLE	IF	CITATIONS
1	Induced pluripotent stem cells for defining Parkinsonian patient subtypes: a further step toward precision medicine. <i>Neural Regeneration Research</i> , 2022, 17, 767.	1.6	4
2	Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway. <i>Molecular Neurobiology</i> , 2022, 59, 2129-2149.	1.9	5
3	Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor Receptor Interaction and Striatal Function. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 1.	0.8	1
4	Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation. <i>Neurobiology of Aging</i> , 2021, 99, 65-78.	1.5	14
5	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. <i>Stem Cell Research</i> , 2021, 51, 102216.	0.3	2
6	Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection. <i>Biomolecules</i> , 2020, 10, 1016.	1.8	28
7	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. <i>Neurobiology of Disease</i> , 2020, 138, 104789.	2.1	19
8	Nuclear Factor- κ B Dysregulation and α -Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 68.	1.7	56
9	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. <i>Stem Cell Research</i> , 2020, 49, 102104.	0.3	1
10	Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer. <i>Neurobiology of Disease</i> , 2019, 129, 1-12.	2.1	25
11	The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons. <i>Biochemical Pharmacology</i> , 2019, 163, 154-168.	2.0	14
12	In vitro antitumor activity of progesterone in human adrenocortical carcinoma. <i>Endocrine</i> , 2019, 63, 592-601.	1.1	21
13	Synapsin III is a key component of α -synuclein fibrils in Lewy bodies of PD brains. <i>Brain Pathology</i> , 2018, 28, 875-888.	2.1	37
14	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. <i>Molecular Neurobiology</i> , 2018, 55, 1054-1067.	1.9	30
15	Palbociclib inhibits proliferation of human adrenocortical tumor cells. <i>Endocrine</i> , 2018, 59, 213-217.	1.1	28
16	Synapsin III deficiency hampers α -synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. <i>Acta Neuropathologica</i> , 2018, 136, 621-639.	3.9	53
17	Dopamine Transporter/ α -Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinson's Disease: An In Situ Proximity Ligation Assay Study. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1611.	1.8	20
18	Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity. <i>European Neuropsychopharmacology</i> , 2017, 27, 313-324.	0.3	27

#	ARTICLE	IF	CITATIONS
19	The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2017, 291, 1-7.	2.0	17
20	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 164-175.	1.3	11
21	The Contribution of α -Synuclein Spreading to Parkinson's Disease Synaptopathy. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	1.0	70
22	Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 512-520.	2.2	14
23	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 77-94.	1.8	163
24	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4594-4602.	1.8	31
25	Mitochondrial Dysfunction and α -Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?. <i>Parkinson's Disease</i> , 2015, 2015, 1-10.	0.6	62
26	Bifunctional compounds targeting both D2 and non-7 nACh receptors: Design, synthesis and pharmacological characterization. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 367-383.	2.6	12
27	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. <i>Neurochemistry International</i> , 2015, 85-86, 14-23.	1.9	30
28	α -synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. <i>Journal of Cell Science</i> , 2015, 128, 2231-2243.	1.2	99
29	The D3 dopamine receptor: From structural interactions to function. <i>European Neuropsychopharmacology</i> , 2015, 25, 1462-1469.	0.3	35
30	GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. <i>Experimental Cell Research</i> , 2014, 323, 100-111.	1.2	61
31	The <i>In Situ</i> Proximity Ligation Assay to Probe Protein-Protein Interactions in Intact Tissues. <i>Methods in Molecular Biology</i> , 2014, 1174, 397-405.	0.4	35
32	Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 54, 339-348.	2.1	33
33	Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling. <i>Molecular Pharmacology</i> , 2013, 83, 1176-1189.	1.0	61
34	From α -synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. <i>Brain Research</i> , 2012, 1476, 183-202.	1.1	89
35	Nerve growth factor, D2 receptor isoforms, and pituitary tumors. <i>Endocrine</i> , 2012, 42, 466-467.	1.1	4
36	Pre-synaptic dopamine D ₃ receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. <i>Journal of Neurochemistry</i> , 2012, 120, 765-778.	2.1	43

#	ARTICLE	IF	CITATIONS
37	Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. <i>Brain Research</i> , 2012, 1432, 95-113.	1.1	39
38	Redistribution of DAT/Î±-Synuclein Complexes Visualized by <i>in Situ</i> Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e27959.	1.1	62
39	Induction of the unfolded protein response by Î±-synuclein in experimental models of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2011, 116, 588-605.	2.1	178
40	The tyrosine phosphatase Shp-2 interacts with the dopamine D ₁ receptor and triggers D ₁ -mediated Erk signaling in striatal neurons. <i>Journal of Neurochemistry</i> , 2011, 117, 253-263.	2.1	25
41	Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. <i>Current Opinion in Pharmacology</i> , 2010, 10, 87-92.	1.7	58
42	Nerve growth factor signaling in prostate health and disease. <i>Growth Factors</i> , 2010, 28, 191-201.	0.5	33
43	The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. <i>Journal of Receptor and Signal Transduction Research</i> , 2010, 30, 347-354.	1.3	36
44	Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract. <i>Neurourology and Urodynamics</i> , 2009, 28, 343-348.	0.8	6
45	Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D ₂ /D ₃ receptor activation. <i>Journal of Neurochemistry</i> , 2008, 106, 560-577.	2.1	74
46	Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. <i>European Journal of Neuroscience</i> , 2008, 28, 1231-1240.	1.2	48
47	Role of receptor heterodimers in the development of l-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S159-S164.	1.1	20
48	Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization. <i>Molecular Pharmacology</i> , 2008, 74, 59-69.	1.0	195
49	Identification and Characterization of Two Nuclear Factor-Î² Sites in the Regulatory Region of the Dopamine D2 Receptor. <i>Endocrinology</i> , 2007, 148, 2563-2570.	1.4	43
50	Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca ⁺⁺ channels and endogenous dopamine. <i>Molecular and Cellular Neurosciences</i> , 2006, 31, 284-292.	1.0	14
51	The NMDA/D1 Receptor Complex as a New Target in Drug Development. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 801-808.	1.0	72
52	Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat. <i>Molecular Pharmacology</i> , 2006, 69, 805-812.	1.0	75
53	Oligomerization of Dopamine D1 and Glutamate NMDA Receptors: A New Mechanism Regulating Striatal Function. , 2005, , 141-149.		0
54	Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase. <i>Molecular Endocrinology</i> , 2004, 18, 162-172.	3.7	18

#	ARTICLE	IF	CITATIONS
55	Increased serum concentration of nerve growth factor in patients with microprolactinoma. <i>Neuropeptides</i> , 2004, 38, 21-24.	0.9	7
56	Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors. <i>Journal of Biological Chemistry</i> , 2003, 278, 20196-20202.	1.6	200
57	Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor- κ B. <i>Molecular Endocrinology</i> , 2002, 16, 353-366.	3.7	66
58	Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. <i>European Journal of Endocrinology</i> , 2002, 147, 371-379.	1.9	12
59	Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. <i>European Journal of Endocrinology</i> , 2002, 147, 407-415.	1.9	22
60	Differential gene expression of dopamine D-2 receptor subtypes in rat chromaffin cells and sympathetic neurons in culture. <i>NeuroReport</i> , 2000, 11, 2467-2471.	0.6	6
61	Growth factors in pituitary tumors. <i>Pituitary</i> , 1999, 1, 153-158.	1.6	15
62	Nerve Growth Factor in Pituitary Development and Pituitary Tumors. <i>Frontiers in Neuroendocrinology</i> , 1998, 19, 128-150.	2.5	34
63	Growth factors in the pathogenesis of prolactin-secreting tumors. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 402-411.	1.8	5
64	Dopamine Receptors: From Structure to Function. <i>Physiological Reviews</i> , 1998, 78, 189-225.	13.1	3,059
65	Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter. <i>Neuron</i> , 1997, 19, 127-138.	3.8	192
66	Opposing roles for D-1 and D-2 dopamine receptors in the regulation of lower esophageal sphincter motility in the rat. <i>Life Sciences</i> , 1994, 54, 1035-1045.	2.0	10
67	Epidermal Growth Factor Promotes Uncoupling from Adenylyl Cyclase of the Rat D _{2S} Receptor Expressed in GH4C1 Cells. <i>Journal of Neurochemistry</i> , 1994, 62, 907-915.	2.1	10
68	L- α -glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. <i>European Journal of Pharmacology</i> , 1992, 211, 351-358.	1.7	65
69	Effects of chronic treatment with L-alpha-glycerylphosphorylcholine on hippocampal cholinergic transmission in the rat. <i>Drug Development Research</i> , 1992, 27, 277-286.	1.4	1
70	Epidermal Growth Factor Induces the Functional Expression of Dopamine Receptors in the GH3 Cell Line*. <i>Endocrinology</i> , 1991, 128, 13-20.	1.4	61
71	Low doses of l-sulpiride down-regulate striatal and cortical dopamine receptors and β -adrenoceptors. <i>European Journal of Pharmacology</i> , 1991, 199, 247-253.	1.7	14
72	Dopaminergic Regulation of Aldosterone Secretion. <i>American Journal of Hypertension</i> , 1990, 3, 93S-95S.	1.0	15

#	ARTICLE	IF	CITATIONS
73	Repeated administration of lisuride down-regulates dopamine D-2 receptor function in mesostriatal and in mesolimbocortical rat brain regions. <i>European Journal of Pharmacology</i> , 1990, 176, 85-90.	1.7	11
74	Evidence for the presence of both D-1 and D-2 dopamine receptors in human esophagus. <i>Life Sciences</i> , 1990, 47, 447-455.	2.0	10
75	Differential effect of acute reserpine administration on D-1 and D-2 dopaminergic receptor density and function in rat striatum. <i>Neurochemistry International</i> , 1989, 14, 61-64.	1.9	9
76	Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding. <i>Brain Research</i> , 1989, 483, 117-122.	1.1	58
77	Dopaminergic Receptor Mechanisms Modulating the Renin-Angiotensin System and Aldosterone Secretion. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, S29-S39.	0.8	6
78	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex. <i>Neuroscience Letters</i> , 1988, 87, 247-252.	1.0	17
79	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. II. Dorsal hippocampus. <i>Neuroscience Letters</i> , 1988, 87, 253-258.	1.0	30
80	Identification and Characterization of Postsynaptic D1- and D2-Dopamine Receptors in the Cardiovascular System. <i>Journal of Cardiovascular Pharmacology</i> , 1988, 11, 643-650.	0.8	45
81	Repeated administration of (α) sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. <i>European Journal of Pharmacology</i> , 1987, 138, 45-51.	1.7	39
82	Striatal adenylate cyclase-inhibiting dopamine D2 receptors are not affected by the aging process. <i>Neuroscience Letters</i> , 1987, 75, 38-42.	1.0	13
83	D2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP. <i>Neuroscience Letters</i> , 1986, 71, 192-196.	1.0	79
84	Characterization of Dopamine Receptors Associated with Aldosterone Secretion in Rat Adrenal Glomerulosa*. <i>Endocrinology</i> , 1986, 119, 2227-2232.	1.4	48
85	Dopamine Uptake is Differentially Regulated in Rat Striatum and Nucleus Accumbens. <i>Journal of Neurochemistry</i> , 1985, 45, 51-56.	2.1	132
86	Identification of D-2 dopaminergic receptors in bovine adrenal cortex. <i>Life Sciences</i> , 1985, 37, 2539-2548.	2.0	15
87	Evidence for the presence of D1 and D2 dopamine receptors in the rat adrenal cortex. <i>European Journal of Pharmacology</i> , 1985, 109, 315-316.	1.7	23